ETA2024 Poster Presentations Clinical thyroid cancer research-2 (10 abstracts)
1Salah Azaiz Institute, Otorhinolaryngology Department, Tunis, Tunisia; 2Salah Azaiz Institute, Otorhinolaryngology Departement, Tunis, Tunisia; 3Salah Azaiz Institute, Nuclear Medicine Department, Tunis, Tunisia
Objective: The aim of this study was to evaluate the response to initial postoperative radioactive iodine therapy (I-131) in patients with papillary thyroid microcarcinoma.
Methods: This was a retrospective study including 123 patients treated for papillary thyroid microcarcinoma with low to intermediate-risk, between 2012 and 2020. These patients underwent total thyroidectomy followed by radioactive iodine therapy (I-131). Clinical examination, thyroglobulin (Tg) levels measurement, ultrasound, and cervico-thoracic scintigraphy (CTS) were performed.
Results: The mean age was 44.4±14.1 years with a female predominance (86.2%). All patients received adjunctive I-131 therapy following total thyroidectomy. The most frequently observed tumor stage was T1aNx, accounting for 31.7% of tumors. Baseline Tg levels measurement and CTS were performed before the first treatment. Response assessment was performed at a median of 6 months following the first treatment. Based on clinical, biological, and radiological criteria, 95 patients (77.2%) were responders to treatment, while 28 patients (22.8%) were non-responders. Therapeutic response significantly varied according to baseline Tg levels and postoperative CTS results (P < 0.001). There was no statistically significant difference in response to the initial treatment regarding patients epidemiological, clinical, and therapeutic data.
Conclusion: Baseline Tg levels >10ng/ml, intense cervical uptake on postoperative CTS, and associated histological lesions are predictive factors of poor response to initial radioiodine therapy. Multicenter studies are warranted to establish a clear consensus regarding the strategy for adjunctive radioiodine therapy administration